Dr. John F Dipersio, M.D., Ph.D.
Claim this profileWashington University School of Medicine
About John F Dipersio, M.D., Ph.D.
Education:
- Holds an MD (Doctor of Medicine).
- Earned a PhD (Doctor of Philosophy).
Experience:
- Since 2017, serves as the Director of the Center for Gene and Cellular Immunotherapy (CGCI) at Washington University School of Medicine, St. Louis, MO.
- From 2000 to 2022, was the Chief of the Division of Oncology at Washington University School of Medicine, St. Louis, MO.
- Has been a Professor of Medicine, Pediatrics, and Pathology/Immunology at Washington University School of Medicine, St. Louis, MO since 1997.
- Awarded the AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research in 2014.
- Received the Daniel P. Schuster Distinguished Translational Investigator Award from Washington University in 2013.
Area of expertise
Acute Myelogenous Leukemia
John F Dipersio, M.D., Ph.D. has run 13 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:
Acute Myeloid Leukemia
John F Dipersio, M.D., Ph.D. has run 10 trials for Acute Myeloid Leukemia. Some of their research focus areas include:
Affiliated Hospitals
Washington University School Of Medicine
Washington University School Of Medicine- Siteman Cancer Center
Clinical Trials John F Dipersio, M.D., Ph.D. is currently running
Dendritic Cells
for Graft-versus-Host Disease
Dendritic cells (DCs) serve as sentries for the immune system. DCs recognize foreign compounds (antigens) in the body, which they internalize and process. When DCs uptake foreign antigens, they migrate to secondary lymphoid organs, where the processed antigens are presented to T cells. Various DC subsets with unique cell lineages, surface protein markers, and tissue localization determinants have been identified. For example, Langerhans cells (LCs) and interstitial dendritic cells (intDCs) are DCs found in stratified epithelia, such as the skin. Though both are expressed in the skin, they differ with respect to their origin and surface protein content and can activate distinct types of immune responses. They may also have different specificities for the capture of antigens and presentation to circulating T cells. To date, it is unknown what role, if any, the different DC populations that reside or repopulate in the skin play in the development and progression of skin graft-versus-host disease (GVHD) following bone marrow transplant.
Recruiting
1 award
N/A
3 criteria
CAR-T Therapy
for Multiple Myeloma
Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease. Although survival has improved, there are nevertheless diminishing durations of response to each subsequent line of therapy. This highlights the need for further therapeutic innovation. BCMA-targeting CAR-T cells show impressive response rates; however, their median duration of response is disappointing. The investigators propose that CS1(SLAMF7)-targeting CAR-T cells will fill a gap in the MM armamentarium. CS1 is an attractive target in MM because it is expressed in most patients. Elotuzumab (Empliciti®), an approved anti-CS1 antibody, has proven the clinical efficacy of this target. CAR-T cells are an ideal modality to target CS1, given that two approved treatments, ide-cel (idecabtagene vicleucel, AbecmaTM) and cilta-cel (ciltacabtagene autoleucel, Carvykti™), have proven the potential for cellular immunotherapy in MM. The investigators are testing the safety and preliminary anti-myeloma efficacy of WS-CART-CS1, a CAR-T cell therapy targeting CS1.
Recruiting
1 award
Phase 1
More about John F Dipersio, M.D., Ph.D.
Clinical Trial Related
1 year of experience running clinical trials · Led 33 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments John F Dipersio, M.D., Ph.D. has experience with
- Duvelisib
- Motixafortide
- Cytokine Induced Memory-like NK Cell Adoptive Therapy
- Isatuximab
- Fludarabine
- VOR33
Breakdown of trials John F Dipersio, M.D., Ph.D. has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Multiple Myeloma
Graft-versus-Host Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John F Dipersio, M.D., Ph.D. specialize in?
John F Dipersio, M.D., Ph.D. focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved CD33 positive patients, or patients who are FLT3 negative.
Is John F Dipersio, M.D., Ph.D. currently recruiting for clinical trials?
Yes, John F Dipersio, M.D., Ph.D. is currently recruiting for 6 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that John F Dipersio, M.D., Ph.D. has studied deeply?
Yes, John F Dipersio, M.D., Ph.D. has studied treatments such as Duvelisib, Motixafortide, Cytokine Induced Memory-like NK Cell Adoptive Therapy.
What is the best way to schedule an appointment with John F Dipersio, M.D., Ph.D.?
Apply for one of the trials that John F Dipersio, M.D., Ph.D. is conducting.
What is the office address of John F Dipersio, M.D., Ph.D.?
The office of John F Dipersio, M.D., Ph.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.